EI
RVMD icon

EAM Investors’s Revolution Medicines RVMD Stock Holding History

EAM Investors’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.24M Sell
49,357
-765
-2% -$112K 0.82% 13
2026
Q1 		$4.87M Sell
50,122
-14,114
-22% -$1.43M 0.56% 55
2025
Q4 		$5.12M Buy
+64,236
New +$4.21M 0.57% 63
2024
Q4 		– Sell
-71,210
Closed -$3.23M – 340
2024
Q3 		$3.23M Sell
71,210
-29,813
-30% -$1.3M 0.48% 111
2024
Q2 		$3.92M Buy
+101,023
New +$3.78M 0.64% 59

Other funds holding RVMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

EAM Investors's RVMD Position: Q2 2026 in Review

EAM Investors reduced its Revolution Medicines (RVMD) stake by 1.5% in Q2 2026, selling an estimated $112K and leaving 49,357 shares worth $9.24M. The position accounts for 0.82% of the portfolio, ranked #13.

EAM Investors first reported a position in RVMD in Q2 2024 and has held it in 5 quarters since. 691 funds tracked by Wall St. Rank hold RVMD as of Q2 2026.

  • EAM Investors held 49,357 shares of Revolution Medicines worth $9.24M as of Q2 2026.
  • EAM Investors sold 765 Revolution Medicines shares in Q2 2026, an estimated $112K.
  • Revolution Medicines made up 0.82% of EAM Investors's portfolio in Q2 2026, its #13 holding.
  • EAM Investors first reported a position in Revolution Medicines in Q2 2024 and has held it in 5 quarters since.
  • 691 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2026.

Based on EAM Investors's 13F filing for Q2 2026, filed 13 Aug 2026.